

Cover Story
Conversation with The Cancer LetterReal-world Evidence
The U.S. Supreme Court’s June 2022 decision to overturn Roe v. Wade has implications that reach far beyond access to reproductive health care services in the 41 states that ban or restrict access to abortion.
In Brief
Clinical Roundup
Drugs & Targets
Trending Stories
- Richard Pazdur left FDA to avoid being part of “the destruction of the American medical system”
- In first NCAB director’s report, Anthony Letai focuses on centralized grant review, budget outlook
- Pazdur leaves FDA after 25-year career that shaped the agency’s oncology regulations
BIO calls for the end of “constant turmoil,” urges the administration to “right the ship” - Pediatric cancer five-year survival rate has increased dramatically, AACR says in inaugural Pediatric Cancer Progress Report
- Anthony Letai pledges to ensure stability for extramural and intramural cancer science
- Vinay Prasad to CBER employees: “It is not wise for FDA to further pollute the scientific literature with papers we cannot defend”




















